Date: 2011-07-13
Type of information: R&D agreement
Compound: Stem cells
Company: Pfizer (USA - NY) Roslin Cells Ltd (UK)
Therapeutic area:
Type agreement: evaluation
R&D
Action mechanism:
Disease:
Details: Roslin Cells, not-for-profit company founded by the Roslin Institute, and Pfizer have signed an agreement for Pfizer to evaluate Roslin’s GMP quality Pluripotent Stem Cells (PSC). The evaluation will allow Pfizer access to Roslin’s Cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin’s GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Financial terms: Financial and commercial details were not disclosed.
Latest news:
